You are here

Application Approved for Novel Gamma-Delta T Cell Therapy for Glioblastoma

First-in-Human Phase 1 Trial Will Begin This Year

The FDA has approved Incysus Therapeutics’ investigational new drug (IND) application for the clinical study of a genetically modified gamma-delta (γδ) T cell in combination with chemotherapy for the treatment of patients with newly diagnosed glioblastoma (GBM).

Incysus’ drug-resistant immunotherapy (DRI) technology is the first genetically modified gamma-delta T-cell product candidate cleared for clinical trials, and a phase 1 trial will commence in 2019. The study will evaluate the safety and activity of the DRI platform, combining standard-of-care chemotherapy with genetically engineered γδ T cells that prove resistant to chemotherapy.

The new technology allows the T cells to attack the tumor when it is most vulnerable. The combination allows the chemotherapy to shrink chemo-sensitive tumor cells, simultaneously disrupting the immune-suppressive tumor microenvironment. In addition, by preserving immune cell function, DRI can upregulate immune-activating markers on the tumor surface to increase tumor immunogenicity.

GBM typically results in death within the first 15 months from diagnosis. It is inherently resistant to conventional therapy and accounts for 52% of all primary brain tumors.

Source: GlobeNewswire, April 1, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs